![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Under the license agreement, Jaguar Health will commercialize Gelclair in the U.S. market. It is indicated to alleviate pain by adhering to the mucosal surface of the mouth and treating oral lesions, including oral mucositis/stomatitis.
Lead Product(s): Maltodextrin
Therapeutic Area: Immunology Product Name: Gelclair
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Jaguar Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2024